Tag: meningococcal vaccines industry size

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Meningococcal Vaccines Market Poised To Hit $6.58 Billion By 2030 With A 9.1% CAGR

The meningococcal vaccines market size has experienced robust growth in recent years. It is projected to increase from $4.26 billion in 2025 to $4.65 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. The expansion observed in the historical period can be attributed to the availability of meningococcal conjugate vaccines, an escalation in the occurrence of meningitis outbreaks, governmental immunization initiatives, expanding pediatric vaccination rates, and enhanced public health funding.

The meningococcal vaccines market is anticipated to experience robust expansion in the coming years. It is projected to reach $6.58 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This growth during the forecast period can be attributed to several factors, including advancements in vaccine technology, the expansion of global immunization programs, a rise in awareness regarding meningococcal disease, the formation of strategic partnerships and collaborations, and an increase in vaccination initiatives targeting adolescents and young adults. Key trends anticipated within this period involve the expansion of pediatric vaccination programs, the development of broad-spectrum meningococcal vaccines, increased government-led immunization efforts, heightened awareness concerning meningococcal disease prevention, and the growth of vaccination campaigns in schools and colleges.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=39311036&type=smp&name=Meningococcal%20Vaccines%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Meningococcal Vaccines Market Demand Drivers Opening New Revenue Streams

The meningococcal vaccine market is anticipated to grow, driven by an uptick in healthcare spending. Healthcare includes institutions providing residential care, nursing facilities, and intermediate care for individuals with mental illnesses or intellectual disabilities. A significant discussion point has been the high cost of newer vaccine generations compared to previous ones, prompting scrutiny into whether their benefits justify their prices. Consequently, assessing the comprehensive social and economic advantages of vaccination is becoming an increasingly vital area of study in the literature concerning vaccine valuation. For instance, an article published by the American Medical Association in April 2025 indicated that U.S. health spending increased by 7.5% in 2023, reaching $4.9 trillion or $14,570 per capita. This expansion rate is considerably higher than the 4.6% increase recorded in 2022. Therefore, the expanding healthcare expenditure is fueling the growth of the meningococcal vaccine market.

Meningococcal Vaccines Market Breakdown By Product Type And Application

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Meningococcal Vaccines Market Trends Powering Strategic Industry Growth

Major companies in the meningococcal vaccines market are developing new vaccines to prevent various serogroups, aiming to boost their market profitability. Meningococcal vaccines are designed as preventive measures to shield individuals from infections caused by specific serogroups of the Neisseria meningitidis bacteria. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company, obtained FDA approval for its vaccine, PENBRAYA. With extensive serogroup coverage, PENBRAYA is the most comprehensive U.S.-approved meningococcal vaccine, protecting against groups A, B, C, W, and Y. The FDA approval is supported by robust Phase 2 and 3 trial data, confirming non-inferior immunogenicity compared to Trumenba + Menveo across all serogroups, alongside a favorable safety profile. Pfizer’s September 2022 announcement had previously revealed positive outcomes from a Phase 3 trial, which assessed PENBRAYA’s safety, tolerability, and immunogenicity against existing licensed meningococcal vaccines.

Meningococcal Vaccines Market Company Landscape And Competitive Strategy

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

View The Full Meningococcal Vaccines Market Report:

https://thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Meningococcal Vaccines Market Regional Analysis And Leading Geography

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Meningococcal Vaccines Market Forecast: What Market Value Is Expected By 2030?

The meningococcal vaccines market has experienced robust expansion over the past few years. Projections indicate it will rise from $4.26 billion in 2025 to $4.65 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.3%. Historically, this growth was driven by factors such as the launch of meningococcal conjugate vaccines, a higher frequency of meningitis outbreaks, government-led immunization initiatives, enhanced vaccination rates among children, and increased funding for public health programs.

The market for meningococcal vaccines is anticipated to experience robust expansion over the coming years, projected to reach $6.58 billion by 2030, with a compound annual growth rate of 9.1%. This forecasted growth is driven by several factors, including improvements in vaccine technology, the broadening of worldwide immunization efforts, heightened public awareness about meningococcal disease, strategic alliances and collaborations, and a rise in vaccination programs targeting adolescents and young adults. Key developments shaping the future of this market include the widening of pediatric immunization schedules, the creation of broad-spectrum meningococcal vaccines, stronger governmental vaccination initiatives, growing focus on preventing meningococcal disease, and an increase in vaccination drives at schools and colleges.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

#Meningococcal Vaccines Market Growth Factors: Which Forces Are Supporting Market Expansion?

The growth of the meningococcal vaccine market is set to be driven by rising healthcare expenditures. Healthcare encompasses establishments like residential care facilities, nursing homes, and intermediate care centers for individuals with mental illnesses or intellectual disabilities. The considerable cost of newer vaccine generations compared to older ones has sparked debates over whether their advantages justify the price tags. Evaluating the full societal and economic benefits of vaccination is gaining traction as a critical focus in vaccine valuation research. For example, in April 2025, the American Medical Association—a U.S.-based professional organization and lobbying group for physicians and medical students—reported that U.S. health spending surged by 7.5% in 2023, reaching $4.9 trillion or $14,570 per person. This marks a notable acceleration from the 4.6% increase seen in 2022. Consequently, the rise in healthcare spending is fueling momentum in the meningococcal vaccine market.

Meningococcal Vaccines Market Segment Landscape And Growth Potential

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Meningococcal Vaccines Market Industry Trends: What Changes Are Reshaping Demand?

Leading players in the meningococcal vaccines sector are working on innovative vaccines aimed at preventing serogroups, with the goal of boosting their market profitability. These vaccines serve as preventive tools, shielding individuals from infections tied to specific serogroups of the Neisseria meningitidis bacteria. For example, in October 2023, Pfizer Inc., a pharmaceutical firm headquartered in the United States, secured FDA approval for its vaccine, PENBRAYA. Offering extensive serogroup protection, this vaccine is the most comprehensive meningococcal vaccine cleared in the U.S., covering groups A, B, C, W, and Y. The FDA’s decision was backed by solid Phase 2 and 3 trial results, which showed non-inferior immunogenicity compared to Trumenba + Menveo across all serogroups, along with a reassuring safety profile. Additionally, an announcement from Pfizer in September 2022 highlighted positive Phase 3 trial findings, where PENBRAYA was assessed against currently licensed meningococcal vaccines regarding safety, tolerability, and immunogenicity.

Meningococcal Vaccines Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

Access The Complete Meningococcal Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Meningococcal Vaccines Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Meningococcal Vaccines Market Over The Forecast Period?

The market size for meningococcal vaccines has experienced significant expansion in recent years. This market is anticipated to expand from $4.26 billion in 2025 to $4.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. The historical growth in this sector is attributable to several factors, including the introduction of meningococcal conjugate vaccines, a rising incidence of meningitis outbreaks, government immunization campaigns, growing pediatric vaccination coverage, and increased public health funding.

The meningococcal vaccines market is anticipated to experience substantial growth over the coming years. Its valuation is projected to reach $6.58 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This expansion during the forecast period is driven by factors such as progress in vaccine technology, the widening scope of global immunization efforts, heightened understanding of meningococcal disease, strategic alliances, and increased vaccination drives targeting adolescents and young adults. Key developments expected during this period involve the broadening of pediatric vaccination programs, the creation of comprehensive broad-spectrum meningococcal vaccines, strengthened government-led immunization campaigns, growing recognition of the importance of preventing meningococcal disease, and an uptick in vaccination initiatives within schools and colleges.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Market Drivers Are Helping Shape The Meningococcal Vaccines Market Expansion?

Rising healthcare expenditure is projected to boost the expansion of the meningococcal vaccine market. Healthcare encompasses establishments such as residential care facilities, nursing homes, and intermediate care facilities catering to individuals with mental illnesses or mental retardation. The considerable cost of newer vaccine generations, when compared to older ones, has become a central point in debates regarding if their advantages warrant their price tags. Evaluating the full societal and economic advantages of vaccination is emerging as an increasingly significant research focus within the literature concerning vaccine valuation. For example, data from an April 2025 article by the American Medical Association, a U.S.-based professional body and lobbying organization for doctors and medical students, showed that U.S. health spending grew by 7.5% in 2023, reaching $4.9 trillion or $14,570 per person. This particular growth rate substantially surpassed the 4.6% increase observed in 2022. Consequently, the rise in healthcare spending is propelling the expansion of the meningococcal vaccine market.

How Is The Meningococcal Vaccines Market Distributed Across Key Segments?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Which Trends Are Contributing To Changes In The Meningococcal Vaccines Market?

Major companies active in the meningococcal vaccines market are developing new vaccines for preventing serogroups, intending to boost their market profitability. Meningococcal vaccines are designed as preventive measures to safeguard individuals from infections caused by specific serogroups of the Neisseria meningitidis bacteria. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company, obtained approval from the FDA for its vaccine, PENBRAYA. PENBRAYA, featuring extensive serogroup coverage, stands as the most comprehensive U.S.-approved meningococcal vaccine, protecting against groups A, B, C, W, and Y. The FDA’s approval is founded on robust Phase 2 and 3 trial data, confirming non-inferior immunogenicity to Trumenba + Menveo across all serogroups, complemented by favorable safety. Pfizer’s announcement in September 2022 had previously unveiled positive results from a Phase 3 trial, comparing PENBRAYA to existing licensed meningococcal vaccines regarding its safety, tolerability, and immunogenicity.

Which Companies Form The Competitive Landscape Of The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

Access The Complete Meningococcal Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Which Region Leads The Meningococcal Vaccines Market By Size?

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Meningococcal Vaccines Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2026, By The Business Research Company

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Meningococcal Vaccines Market Between 2026 And 2030?

The meningococcal vaccines market has seen substantial growth over recent years. It is anticipated to increase from $4.26 billion in 2025 to $4.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. Historically, this growth has stemmed from factors such as the introduction of meningococcal conjugate vaccines, an uptick in meningitis outbreaks, government immunization efforts, broader pediatric vaccination coverage, and enhanced public health funding.

The meningococcal vaccines market is anticipated to observe robust expansion over the next few years. It is projected to climb to $6.58 billion in 2030, achieving a compound annual growth rate (CAGR) of 9.1%. This growth during the forecast period can be attributed to advancements in vaccine technology, the broadening of global immunization programs, increased awareness regarding meningococcal disease, the establishment of strategic partnerships and collaborations, and a rise in vaccination initiatives for adolescents and young adults. Significant trends expected during this period include the expansion of pediatric vaccination programs, the development of broad-spectrum meningococcal vaccines, enhanced government immunization initiatives, increasing knowledge about meningococcal disease prevention, and the growth of school and college vaccination campaigns.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Major Factors Are Driving The Meningococcal Vaccines Market Forward?

Rising healthcare expenditure is anticipated to drive the expansion of the meningococcal vaccine market in the future. Healthcare, in this context, refers to residential care institutions, nursing facilities, intermediate care facilities for individuals with mental illnesses, or intermediate care facilities for people with mental retardation. The significant cost of advanced vaccine generations compared to earlier ones has become a crucial point of discussion regarding whether the benefits of these new vaccinations justify their price. Consequently, assessing the comprehensive social and economic advantages of vaccination is becoming an increasingly vital area of research in valuing vaccination. As an illustration, in April 2025, an article published by the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, indicated that Health spending in the U.S. climbed by 7.5% in 2023, reaching $4.9 trillion or $14,570 per capita. This growth rate is considerably higher than the 4.6% increase observed in 2022. Therefore, an uptick in healthcare spending is fueling the growth of the meningococcal vaccine market.

What Are The Key Segment Divisions In The Meningococcal Vaccines Market Segment Structure?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

What Trends Are Affecting The Direction Of The Meningococcal Vaccines Market?

Leading companies in the meningococcal vaccines market are engaged in developing new vaccines for the prevention of serogroups, aiming to increase their profitability. Meningococcal vaccines function as preventive measures, designed to protect individuals from infections caused by specific serogroups of the bacteria Neisseria meningitidis. As an illustration, in October 2023, Pfizer Inc., a US-based pharmaceutical company, obtained FDA approval for the vaccine PENBRAYA. Offering extensive serogroup coverage, PENBRAYA is the most comprehensive U.S.-approved meningococcal vaccine, providing protection against groups A, B, C, W, and Y. The FDA approval is rooted in strong Phase 2 and 3 trial data, which confirmed non-inferior immunogenicity compared to Trumenba + Menveo across all serogroups, coupled with a favorable safety profile. Earlier, Pfizer’s September 2022 announcement disclosed positive results from a Phase 3 trial, where PENBRAYA was compared against existing licensed meningococcal vaccines in terms of its safety, tolerability, and immunogenicity.

Which Organizations Are Engaged In The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

Get The Full Meningococcal Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Which Geographic Region Dominates The Meningococcal Vaccines Market?

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Meningococcal Vaccines Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2026, By The Business Research Company

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Meningococcal Vaccines Market At The End Of The 2026–2030 Forecast Period?

The meningococcal vaccines market has shown strong expansion in recent years. This market is set to grow from $4.26 billion in 2025 to $4.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. The historical increase can be attributed to factors such as the introduction of meningococcal conjugate vaccines, an uptick in meningitis outbreaks, various government immunization campaigns, increasing pediatric vaccination coverage, and augmented public health funding.

The meningococcal vaccines market is projected to experience substantial expansion in the coming years, reaching a valuation of $6.58 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.1%. This anticipated growth stems from advancements in vaccine technology, the broader reach of global immunization initiatives, heightened awareness of meningococcal disease, strategic alliances and partnerships, and an increase in vaccination efforts targeting adolescents and young adults. Key developments expected during this forecast period include the expansion of pediatric vaccination schemes, the creation of wide-ranging meningococcal vaccines, strengthened government-backed immunization programs, greater public understanding of meningococcal disease prevention, and the proliferation of vaccination campaigns in schools and colleges.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Primary Drivers Are Shaping The Development Of The Meningococcal Vaccines Market?

The rising expenditure on healthcare is anticipated to drive the expansion of the meningococcal vaccine market in the future. Healthcare encompasses establishments such as residential care institutions, nursing facilities, and intermediate care facilities for individuals with mental illnesses or mental retardation. A crucial aspect in debates regarding the value of new vaccinations is the significantly higher cost of contemporary vaccine generations compared to earlier ones, questioning if their advantages warrant the price. Evaluating the full societal and economic advantages of vaccination is emerging as an increasingly significant research focus within the literature concerning vaccination valuation. For example, an article from April 2025 by the American Medical Association, a US professional and lobbying body for doctors and medical students, noted that U.S. health spending grew by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person. This expansion rate notably surpassed the 4.6% increase observed in 2022. Consequently, heightened healthcare expenditure is fueling the expansion of the meningococcal vaccine market.

What Segment Types Make Up The Meningococcal Vaccines Market?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Which Market Trends Are Creating New Opportunities In The Meningococcal Vaccines Market?

Leading companies in the meningococcal vaccines market are actively developing new vaccines to prevent various serogroups, aiming to enhance their market profitability. These meningococcal vaccines serve as critical preventive measures, designed to protect individuals from infections caused by specific serogroups of the Neisseria meningitidis bacteria. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company, secured approval from FDA for its vaccine PENBRAYA. PENBRAYA is recognized as the most comprehensive U.S.-approved meningococcal vaccine, providing extensive serogroup coverage and safeguarding against groups A, B, C, W, and Y. The FDA approval for PENBRAYA was supported by robust Phase 2 and 3 trial data, which confirmed its non-inferior immunogenicity compared to Trumenba + Menveo across all serogroups, coupled with a favorable safety profile. This development follows Pfizer’s September 2022 announcement, detailing positive outcomes from a Phase 3 trial that evaluated PENBRAYA against existing licensed meningococcal vaccines for safety, tolerability, and immunogenicity.

Who Are The Key Players Driving Competition In The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

Read the full meningococcal vaccines market report here:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

How Does The Meningococcal Vaccines Market Perform Across Major Global Regions?

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Meningococcal Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2026, By The Business Research Company

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Meningococcal Vaccines Market At The End Of The 2026–2030 Forecast Period?

The meningococcal vaccines market has shown strong expansion in recent years. This market is set to grow from $4.26 billion in 2025 to $4.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. The historical increase can be attributed to factors such as the introduction of meningococcal conjugate vaccines, an uptick in meningitis outbreaks, various government immunization campaigns, increasing pediatric vaccination coverage, and augmented public health funding.

The meningococcal vaccines market is projected to experience substantial expansion in the coming years, reaching a valuation of $6.58 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.1%. This anticipated growth stems from advancements in vaccine technology, the broader reach of global immunization initiatives, heightened awareness of meningococcal disease, strategic alliances and partnerships, and an increase in vaccination efforts targeting adolescents and young adults. Key developments expected during this forecast period include the expansion of pediatric vaccination schemes, the creation of wide-ranging meningococcal vaccines, strengthened government-backed immunization programs, greater public understanding of meningococcal disease prevention, and the proliferation of vaccination campaigns in schools and colleges.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Primary Drivers Are Shaping The Development Of The Meningococcal Vaccines Market?

The rising expenditure on healthcare is anticipated to drive the expansion of the meningococcal vaccine market in the future. Healthcare encompasses establishments such as residential care institutions, nursing facilities, and intermediate care facilities for individuals with mental illnesses or mental retardation. A crucial aspect in debates regarding the value of new vaccinations is the significantly higher cost of contemporary vaccine generations compared to earlier ones, questioning if their advantages warrant the price. Evaluating the full societal and economic advantages of vaccination is emerging as an increasingly significant research focus within the literature concerning vaccination valuation. For example, an article from April 2025 by the American Medical Association, a US professional and lobbying body for doctors and medical students, noted that U.S. health spending grew by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person. This expansion rate notably surpassed the 4.6% increase observed in 2022. Consequently, heightened healthcare expenditure is fueling the expansion of the meningococcal vaccine market.

What Segment Types Make Up The Meningococcal Vaccines Market?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Which Market Trends Are Creating New Opportunities In The Meningococcal Vaccines Market?

Leading companies in the meningococcal vaccines market are actively developing new vaccines to prevent various serogroups, aiming to enhance their market profitability. These meningococcal vaccines serve as critical preventive measures, designed to protect individuals from infections caused by specific serogroups of the Neisseria meningitidis bacteria. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company, secured approval from FDA for its vaccine PENBRAYA. PENBRAYA is recognized as the most comprehensive U.S.-approved meningococcal vaccine, providing extensive serogroup coverage and safeguarding against groups A, B, C, W, and Y. The FDA approval for PENBRAYA was supported by robust Phase 2 and 3 trial data, which confirmed its non-inferior immunogenicity compared to Trumenba + Menveo across all serogroups, coupled with a favorable safety profile. This development follows Pfizer’s September 2022 announcement, detailing positive outcomes from a Phase 3 trial that evaluated PENBRAYA against existing licensed meningococcal vaccines for safety, tolerability, and immunogenicity.

Who Are The Key Players Driving Competition In The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

Read the full meningococcal vaccines market report here:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

How Does The Meningococcal Vaccines Market Perform Across Major Global Regions?

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Meningococcal Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2026, By The Business Research Company

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Meningococcal Vaccines Market At The End Of The 2026–2030 Forecast Period?

The meningococcal vaccines market has shown strong expansion in recent years. This market is set to grow from $4.26 billion in 2025 to $4.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. The historical increase can be attributed to factors such as the introduction of meningococcal conjugate vaccines, an uptick in meningitis outbreaks, various government immunization campaigns, increasing pediatric vaccination coverage, and augmented public health funding.

The meningococcal vaccines market is projected to experience substantial expansion in the coming years, reaching a valuation of $6.58 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.1%. This anticipated growth stems from advancements in vaccine technology, the broader reach of global immunization initiatives, heightened awareness of meningococcal disease, strategic alliances and partnerships, and an increase in vaccination efforts targeting adolescents and young adults. Key developments expected during this forecast period include the expansion of pediatric vaccination schemes, the creation of wide-ranging meningococcal vaccines, strengthened government-backed immunization programs, greater public understanding of meningococcal disease prevention, and the proliferation of vaccination campaigns in schools and colleges.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Primary Drivers Are Shaping The Development Of The Meningococcal Vaccines Market?

The rising expenditure on healthcare is anticipated to drive the expansion of the meningococcal vaccine market in the future. Healthcare encompasses establishments such as residential care institutions, nursing facilities, and intermediate care facilities for individuals with mental illnesses or mental retardation. A crucial aspect in debates regarding the value of new vaccinations is the significantly higher cost of contemporary vaccine generations compared to earlier ones, questioning if their advantages warrant the price. Evaluating the full societal and economic advantages of vaccination is emerging as an increasingly significant research focus within the literature concerning vaccination valuation. For example, an article from April 2025 by the American Medical Association, a US professional and lobbying body for doctors and medical students, noted that U.S. health spending grew by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person. This expansion rate notably surpassed the 4.6% increase observed in 2022. Consequently, heightened healthcare expenditure is fueling the expansion of the meningococcal vaccine market.

What Segment Types Make Up The Meningococcal Vaccines Market?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Which Market Trends Are Creating New Opportunities In The Meningococcal Vaccines Market?

Leading companies in the meningococcal vaccines market are actively developing new vaccines to prevent various serogroups, aiming to enhance their market profitability. These meningococcal vaccines serve as critical preventive measures, designed to protect individuals from infections caused by specific serogroups of the Neisseria meningitidis bacteria. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company, secured approval from FDA for its vaccine PENBRAYA. PENBRAYA is recognized as the most comprehensive U.S.-approved meningococcal vaccine, providing extensive serogroup coverage and safeguarding against groups A, B, C, W, and Y. The FDA approval for PENBRAYA was supported by robust Phase 2 and 3 trial data, which confirmed its non-inferior immunogenicity compared to Trumenba + Menveo across all serogroups, coupled with a favorable safety profile. This development follows Pfizer’s September 2022 announcement, detailing positive outcomes from a Phase 3 trial that evaluated PENBRAYA against existing licensed meningococcal vaccines for safety, tolerability, and immunogenicity.

Who Are The Key Players Driving Competition In The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

Read the full meningococcal vaccines market report here:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

How Does The Meningococcal Vaccines Market Perform Across Major Global Regions?

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Meningococcal Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2026, By The Business Research Company

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the meningococcal vaccines market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Meningococcal Vaccines Market by the end of 2030?

The meningococcal vaccines market has observed substantial growth in recent years. It is anticipated to expand from $4.26 billion in 2025 to $4.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. The drivers for this past growth include the introduction of meningococcal conjugate vaccines, an increasing frequency of meningitis outbreaks, government-led immunization programs, expanding pediatric vaccination rates, and greater public health funding.

The meningococcal vaccines market is projected to experience substantial expansion in the coming years. This market is forecast to reach $6.58 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. Factors driving this growth during the forecast period include advances in vaccine technology, the broadening of global immunization efforts, heightened public awareness of meningococcal disease, strategic alliances and joint ventures, and the expansion of vaccination programs targeting adolescents and young adults. Key trends expected over the forecast horizon encompass the enlargement of pediatric vaccination schemes, the creation of comprehensive broad-spectrum meningococcal vaccines, a rise in governmental immunization endeavors, growing understanding of meningococcal disease prevention, and the proliferation of vaccination campaigns in educational institutions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

What Drivers Are Shaping Future Opportunities In The Meningococcal Vaccines Market?

Increased healthcare spending is anticipated to propel the meningococcal vaccine market forward. Healthcare refers to a residential care institution, nursing facility, intermediate care facility for people with mental illnesses, or intermediate care facility for people with mental retardation. The substantial cost of newer vaccine generations, when compared to their predecessors, is a key consideration in debates over whether their benefits justify their price. Evaluating the comprehensive social and economic benefits of vaccination is becoming an increasingly significant area of inquiry in vaccination valuation literature. For instance, in April 2025, an article by the American Medical Association, a US-based professional association for physicians and medical students, revealed that Health spending in the U.S. rose by 7.5% in 2023, reaching $4.9 trillion or $14,570 per capita. This growth rate surpassed the 4.6% increase recorded in 2022. Thus, the escalating healthcare spending is driving the expansion of the meningococcal vaccine market.

Which Segments Are Gaining Traction In The Meningococcal Vaccines Market?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

What Upcoming Trends Are Likely To Define The Future Path Of The Meningococcal Vaccines Market?

Leading companies in the meningococcal vaccines market are developing novel vaccines for the prevention of serogroups to increase their market profitability. Meningococcal vaccines are designed as preventive measures to protect individuals against infections caused by specific serogroups of the Neisseria meningitidis bacteria. For instance, in October 2023, Pfizer Inc., a pharmaceutical company based in the US, received approval from FDA for its vaccine, PENBRAYA. PENBRAYA, providing extensive serogroup coverage, stands as the most comprehensive U.S.-approved meningococcal vaccine, safeguarding against groups A, B, C, W, and Y. The FDA approval is supported by robust Phase 2 and 3 trial data, confirming non-inferior immunogenicity to Trumenba + Menveo across all serogroups, coupled with a favorable safety profile. Pfizer’s announcement in September 2022 had previously revealed positive outcomes from a Phase 3 trial, comparing PENBRAYA to existing licensed meningococcal vaccines regarding safety, tolerability, and immunogenicity.

Who Are The Major Companies Operating In The Meningococcal Vaccines Market?

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Meningococcal Vaccines Market?

North America was the largest region in the meningococcal vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Meningococcal Vaccines Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

Browse Through More Reports Similar to the Global Meningococcal Vaccines Market 2026, By The Business Research Company

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model